Clinical Trials for Pancreas Cancer

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic pancreatic ductal adenocarcinoma who have achieved at least stable disease after ≥16 weeks of first-line chemotherapy (ECOG 0–1) receive maintenance nivolumab plus SX-682, an oral allosteric CXCR1/2 inhibitor designed to block MDSC trafficking and remodel the tumor microenvironment. Single-arm dose escalation of SX-682 (25–400 mg BID) with nivolumab 240 mg IV q2w; paired biopsies required.

ClinicalTrials.gov ID: NCT04477343

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic pancreatic ductal adenocarcinoma harboring pathogenic germline or somatic BRCA1/2 or PALB2 mutations after progression on FOLFIRINOX/NALIRIFOX are randomized to nab-paclitaxel/gemcitabine with or without cisplatin. The investigational addition is cisplatin, a DNA crosslinking platinum agent expected to exploit homologous recombination deficiency in this population.

ClinicalTrials.gov ID: NCT06115499

Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with advanced solid tumors in dose escalation and expansion cohorts of previously treated metastatic pancreatic cancer or unresectable stage III/IV melanoma harboring RAS mutations or NF1 loss (excluding BRAFV600), treated with oral ulixertinib (ERK1/2 inhibitor targeting MAPK) plus palbociclib (CDK4/6 inhibitor). Melanoma cohort generally requires prior PD‑1/PD‑L1 therapy; measurable disease is required and controlled brain metastases are allowed only in the RAS/NF1‑mutant melanoma cohort under specified conditions.

ClinicalTrials.gov ID: NCT03454035

A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma (ECOG 0–2) with a ≤5 cm lesion amenable to implantation receive standard mFOLFIRINOX plus intratumoral Alpha DaRT, an Ra-224–based brachytherapy delivering short-range alpha particles for local cytotoxicity. Key aims include safety, pain control, and, in locally advanced cases, potential conversion to resectability.

ClinicalTrials.gov ID: NCT06698458

A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (ARTIA-Pancreas)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with borderline-resectable, locally advanced, or medically inoperable pancreatic adenocarcinoma after ≥2 months of induction chemotherapy receive ablative stereotactic adaptive radiotherapy (50 Gy in 5 fractions) using daily adaptive planning on Varian Ethos, with systemic therapy held during RT. The study focuses on minimizing acute and late GI toxicity while assessing local control and survival.

ClinicalTrials.gov ID: NCT05764720

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with well-differentiated (G1–2), SSTR-positive gastroenteropancreatic NETs with hepatic metastases undergo cytoreductive surgery followed within 90 days by standard PRRT with lutetium Lu 177 dotatate (a radiolabeled somatostatin analog delivering beta radiation to SSTR-expressing cells) every 8 weeks for up to 4 cycles. Excludes G3 disease, inoperable tumors >3 cm, prior PRRT, and uncontrolled comorbidities; outcomes include PFS, ORR by RECIST, safety, and SSTR-PET changes.

ClinicalTrials.gov ID: NCT06016855

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with histologically confirmed pancreatic ductal adenocarcinoma and nominal oligometastatic disease (1–5 lesions), ECOG 0–2, eligible for definitive local therapy to all sites, are randomized to standard systemic therapy alone versus systemic therapy plus comprehensive metastasis-directed therapy (e.g., SBRT/external-beam RT, surgery, ablation, or embolization to all known sites, including the primary). Suitable for patients without malignant effusions/peritoneal carcinomatosis and with recent imaging confirming oligometastatic status; prior induction to oligometastatic state allowed if sustained ≥6 months.

ClinicalTrials.gov ID: NCT06593431

Phase 2 Randomized Trial of Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Pancreatic Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with histologically confirmed oligometastatic pancreatic adenocarcinoma (≤5 extracranial metastases, all SBRT-amenable; ECOG 0–2) are randomized to standard metastatic chemotherapy (e.g., FOLFIRINOX or gemcitabine-based) with or without SBRT to all metastatic sites. Crossover to SBRT is allowed for local progression without new metastases; outcomes include PFS, response, OS, and safety.

ClinicalTrials.gov ID: NCT04975516

A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced/metastatic pancreatic cancer harboring FGFR alterations receive oral pemigatinib (FGFR1–3 tyrosine kinase inhibitor) in 21‑day cycles; Cohort 1 requires FGFR2 fusion/translocation and KRAS-wild type, while Cohort 2 includes other activating FGFR1/2/3/4 alterations (KRAS co-mutations allowed), all after progression/intolerance to standard therapy and no prior FGFR inhibitor. Single-arm telemedicine study assessing response, PFS, and safety, with attention to class‑typical toxicities (e.g., hyperphosphatemia, ocular events).

ClinicalTrials.gov ID: NCT06906562

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with well-differentiated (G1–2), SSTR-positive pancreatic NETs that are unresectable/metastatic and have progressed after ≥1 prior systemic therapy (no prior PRRT or fulvestrant) receive 177Lu-DOTATATE plus fulvestrant. Fulvestrant, a selective estrogen receptor degrader with potential radiosensitizing effects, is combined with standard PRRT to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06663072